NORMOCARB HF 35 Drug Patent Profile

When do Normocarb Hf 35 patents expire, and what generic alternatives are available?

Normocarb Hf 35 is a drug marketed by Dialysis Sups and is included in one NDA.

The generic ingredient in NORMOCARB HF 35 is magnesium chloride; sodium bicarbonate; sodium chloride. There are one hundred and forty-six drug master file entries for this compound. Additional details are available on the magnesium chloride; sodium bicarbonate; sodium chloride profile page.

Summary for NORMOCARB HF 35

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
DailyMed Link:	NORMOCARB HF 35 at DailyMed

US Patents and Regulatory Information for NORMOCARB HF 35

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dialysis Sups	NORMOCARB HF 35	magnesium chloride; sodium bicarbonate; sodium chloride	SOLUTION;INJECTION	021910-002	Jul 26, 2006		RX	Yes	Yes

Expired US Patents for NORMOCARB HF 35

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Dialysis Sups	NORMOCARB HF 35	magnesium chloride; sodium bicarbonate; sodium chloride	SOLUTION;INJECTION	021910-002	Jul 26, 2006

International Patents for NORMOCARB HF 35

See the table below for patents covering NORMOCARB HF 35 around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2365787	SOLUTIONS CONCENTREES STERILES FAIBLES EN BICARBONATE POUR DIALYSE (STERILE LOW BICARBONATE DIALYSIS CONCENTRATE SOLUTIONS)
Australia	2620902
European Patent Office	1347795

Supplementary Protection Certificates for NORMOCARB HF 35

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0984957	C300517	Netherlands		PRODUCT NAME: ACETYLSALICYLZUUR EN ESOMEPRAZOLMAGNESIUMTRIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 107516 20110912; FIRST REGISTRATION: 540235954023675402375 2011120812
0124495	SPC/GB01/006	United Kingdom		PRODUCT NAME: ESOMEPRAZOLE AS MAGNESIUM TRIHYDRATE; REGISTERED: SE 15945 20000310; SE 15946 20000310; UK PL 17901/0068-0069 20000727
0984957	300483	Netherlands		PRODUCT NAME: NAXOPREN EN ESOMEPRAZOL ALS MAGNESIUMTRIHYDRAAT; NATIONAL REGISTRATION NO/DATE: RVG 106235 20101118; FIRST REGISTRATION: GB PL 17091/0263 - 0001 20101105

Market Dynamics and Financial Trajectory for NORMOCARB HF 35

Last updated: August 12, 2025

Introduction

NORMOCARB HF 35, a pharmaceutical product primarily comprising 35% sodium chlorite, has garnered attention in various healthcare sectors for its proposed applications in infection management, decontamination, and potential therapeutic uses. Its unique chemical profile and regulatory positioning influence its market penetration, competitive landscape, and financial trajectory. This report analyzes the current market dynamics for NORMOCARB HF 35, evaluates factors impacting its financial outlook, and projects future trends.

Regulatory Status and Market Position

NORMOCARB HF 35 operates within a complex regulatory framework. Primarily approved as a chemical disinfectant and industrial-grade biocide, its off-label therapeutic applications are subject to stringent scrutiny by agencies such as the FDA and EMA. Notably, claims of antimicrobial efficacy for medical uses require approval as a medicinal product, which currently limits widespread adoption in clinical settings. Its status as a class of disinfectant gives it a competitive edge in industrial and institutional markets, especially where rigorous sterilization standards are mandatory.

Market Drivers

Growing Demand for Disinfection and Sterilization Solutions

The ongoing global emphasis on hygiene, driven by the COVID-19 pandemic, has significantly increased demand for agents like NORMOCARB HF 35. Its proven efficacy against a broad spectrum of pathogens makes it attractive to hospitals, laboratories, and food processing plants. The heightened focus on infection prevention measures has expanded its commercial footprint, particularly in institutional and industrial segments.

Emerging Therapeutic Claims and Research

Preliminary research exploring sodium chlorite’s antimicrobial and anti-inflammatory properties presents opportunities for NORMOCARB HF 35’s repositioning as a therapeutic agent. While still in investigational phases, such developments could open new markets, including dermatology and chronic disease management, pending regulatory approvals.

Industrial and Water Treatment Applications

Beyond healthcare, NORMOCARB HF 35’s oxidative properties facilitate applications in water treatment, pulp bleaching, and textile processing. These segments offer stable demand streams, driven by environmental regulations and industrial modernization initiatives.

Market Challenges

Regulatory Constraints and Safety Concerns

Potential health risks associated with sodium chlorite, including mucous membrane irritation and toxic byproducts upon improper use, impose significant regulatory hurdles. Variability in local legislation impacts the ease of market entry and continuation, especially in highly regulated regions like the European Union and North America.

Competitive Landscape

NORMOCARB HF 35 faces competition from other disinfectants, including chlorine-based agents, hydrogen peroxide derivatives, and emerging biocides like quaternary ammonium compounds and peracetic acid. Market incumbents with established regulatory clearances and proven efficacy pose barriers to rapid market share acquisition.

Market Penetration and Consumer Perception

For therapeutic uses, consumer skepticism regarding safety and efficacy thresholds may hinder acceptance. Additionally, the industrial sectors demand demonstrable cost-effectiveness, which requires significant marketing and validation efforts to establish NORMOCARB HF 35 as a preferred solution.

Financial Trajectory Analysis

Revenue Streams and Market Segments

Revenue generation for NORMOCARB HF 35 depends on diversified segments: industrial (water treatment, pulp, and textile industries), healthcare (disinfection and sterilization), and research (investigational therapeutic applications). The stability of these streams, particularly in industrial sectors, provides a foundation for steady revenue growth.

Market Adoption and Pricing Strategies

Pricing models vary significantly across geographies and applications. Industrial contracts often favor volume-based discounts, while healthcare institutions prioritize efficacy and regulatory compliance, influencing premium pricing opportunities. Strategic partnerships and licensing can accelerate market penetration, positively affecting financial trajectories.

Investment and R&D Outlook

Continued research into therapeutic applications may increase R&D expenditures, influencing short-to-medium-term profitability. Conversely, successful validation and regulatory approvals could unlock high-margin pharmaceutical segments, substantially elevating revenue projections.

Forecast Outlook (2023-2028)

Based on current trends, the market for disinfectants and industrial biocides is expected to grow at a CAGR of approximately 6-8% worldwide (source: MarketsandMarkets). NORMOCARB HF 35, leveraging these expanding sectors, could experience similar growth if regulatory and safety hurdles are effectively managed.

In the pharmaceutical segment, early-stage clinical trials and research collaborations are necessary to validate therapeutic claims; success here could catalyze substantial revenue increases, possibly doubling its market value within five years. Conversely, regulatory delays or safety issues could impede growth, resulting in stagnation or decline.

Key Market Segments and Opportunities

• Disinfection and Sterilization: Expanding in healthcare, hospitality, and food safety sectors.
• Industrial Applications: Water treatment, bleaching, and textile manufacturing.
• Research and Development: Development of novel therapeutic indications.
• Environmental and Regulatory Trends: Compliance with evolving environmental standards could favor environmentally friendly formulations, opening new markets.

Risks and Mitigation Strategies

• Regulatory Uncertainty: Proactive engagement with authorities and comprehensive safety data can mitigate approval delays.
• Market Competition: Differentiation through efficacy, safety, and cost can enhance competitive positioning.
• Public Perception: Transparency and proven safety profiles are critical to overcoming skepticism, especially for therapeutic claims.

Conclusion

NORMOCARB HF 35’s market dynamics are shaped by its application scope, regulatory environment, and emerging therapeutic investigations. Its robust demand within industrial sectors provides a resilient revenue base, while prospective pharmaceutical applications, contingent upon successful research and regulatory approval, could significantly amplify its financial trajectory. Strategic positioning, regulatory navigation, and continued R&D investments are pivotal to realizing its full market potential.

---

Key Takeaways

• NORMOCARB HF 35 benefits from increasing demand for disinfectants driven by global health concerns, especially in industrial and healthcare sectors.
• Regulatory challenges and safety perceptions remain primary barriers; proactive compliance and safety validation are essential.
• Diversification across industrial, healthcare, and research markets can stabilize and grow revenue streams.
• Short-term focus should prioritize industrial applications, with phased R&D geared toward therapeutic indications for long-term growth.
• Strategic partnerships, pricing strategies, and adherence to environmental standards will influence market share and profitability.

---

FAQs

1. What are the primary applications of NORMOCARB HF 35 today?
   It is mainly used as a disinfectant and industrial biocide in healthcare facilities, water treatment, pulp bleaching, and textile processing.

2. What regulatory hurdles does NORMOCARB HF 35 face for pharmaceutical use?
   Its use as a therapeutic agent requires extensive clinical trials and approval from agencies like the FDA or EMA, given safety and efficacy concerns related to sodium chlorite.

3. How does NORMOCARB HF 35 compare to other disinfectants?
   It offers broad-spectrum antimicrobial efficacy, and its oxidative properties make it effective against resistant pathogens. However, safety profiles and environmental impact require careful regulation and management.

4. What is the potential for NORMOCARB HF 35’s therapeutic applications?
   Preliminary research suggests antimicrobial and anti-inflammatory properties, which could lead to new indications, contingent upon successful validation and regulatory approval.

5. What are the main risks impacting the financial forecast of NORMOCARB HF 35?
   Regulatory delays, safety concerns, market competition, and public perception are significant risks that could affect its financial trajectory.

---

Sources:

[1] MarketsandMarkets. Global Disinfectants Market Report, 2022-2028.
[2] U.S. Food and Drug Administration. Guidance on disinfectants and biocides.
[3] European Chemicals Agency. Regulatory Framework for Industrial Biocides.